Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

NCT01934127 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

427

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Investigational H7N1 vaccine GSK2789869A
BIOLOGICAL: Investigational H7N1 vaccine GSK2789868A
BIOLOGICAL: Placebo

Sponsor

GlaxoSmithKline